nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—MAPK7—retina—ocular cancer	0.00507	0.021	CbGeAlD
Crizotinib—EPHA8—eye—ocular cancer	0.00507	0.021	CbGeAlD
Crizotinib—MET—eye—ocular cancer	0.00479	0.0199	CbGeAlD
Crizotinib—MET—retina—ocular cancer	0.00475	0.0197	CbGeAlD
Crizotinib—NEK9—lymphoid tissue—ocular cancer	0.00445	0.0185	CbGeAlD
Crizotinib—EPHA3—eye—ocular cancer	0.00443	0.0184	CbGeAlD
Crizotinib—ACVR1B—eye—ocular cancer	0.00443	0.0184	CbGeAlD
Crizotinib—EPHA3—retina—ocular cancer	0.00439	0.0182	CbGeAlD
Crizotinib—MET—epithelium—ocular cancer	0.00438	0.0182	CbGeAlD
Crizotinib—EPHA5—eye—ocular cancer	0.00392	0.0162	CbGeAlD
Crizotinib—EPHA5—retina—ocular cancer	0.00388	0.0161	CbGeAlD
Crizotinib—MAP4K1—retina—ocular cancer	0.0038	0.0158	CbGeAlD
Crizotinib—IGF1R—eye—ocular cancer	0.00377	0.0156	CbGeAlD
Crizotinib—BLK—lymphoid tissue—ocular cancer	0.00376	0.0156	CbGeAlD
Crizotinib—STK3—eye—ocular cancer	0.00366	0.0152	CbGeAlD
Crizotinib—MAPK7—lymphoid tissue—ocular cancer	0.00361	0.0149	CbGeAlD
Crizotinib—TXK—lymphoid tissue—ocular cancer	0.00361	0.0149	CbGeAlD
Crizotinib—TESK1—eye—ocular cancer	0.00354	0.0147	CbGeAlD
Crizotinib—BMPR1B—epithelium—ocular cancer	0.00351	0.0146	CbGeAlD
Crizotinib—IGF1R—epithelium—ocular cancer	0.00344	0.0143	CbGeAlD
Crizotinib—MERTK—eye—ocular cancer	0.00344	0.0143	CbGeAlD
Crizotinib—MERTK—retina—ocular cancer	0.00341	0.0141	CbGeAlD
Crizotinib—MET—lymphoid tissue—ocular cancer	0.00337	0.014	CbGeAlD
Crizotinib—TIE1—epithelium—ocular cancer	0.00335	0.0139	CbGeAlD
Crizotinib—MAP3K12—eye—ocular cancer	0.00333	0.0138	CbGeAlD
Crizotinib—ACVR1—eye—ocular cancer	0.00333	0.0138	CbGeAlD
Crizotinib—ACVR1—retina—ocular cancer	0.0033	0.0137	CbGeAlD
Crizotinib—CDK7—lymphoid tissue—ocular cancer	0.00326	0.0135	CbGeAlD
Crizotinib—RIPK2—eye—ocular cancer	0.00301	0.0125	CbGeAlD
Crizotinib—RIPK2—retina—ocular cancer	0.00298	0.0124	CbGeAlD
Crizotinib—JAK3—lymphoid tissue—ocular cancer	0.00298	0.0123	CbGeAlD
Crizotinib—PLK4—lymphoid tissue—ocular cancer	0.00294	0.0122	CbGeAlD
Crizotinib—STK4—lymphoid tissue—ocular cancer	0.00292	0.0121	CbGeAlD
Crizotinib—TBK1—eye—ocular cancer	0.00279	0.0116	CbGeAlD
Crizotinib—TYK2—eye—ocular cancer	0.00278	0.0115	CbGeAlD
Crizotinib—ALK—lymphoid tissue—ocular cancer	0.00276	0.0114	CbGeAlD
Crizotinib—FER—lymphoid tissue—ocular cancer	0.00276	0.0114	CbGeAlD
Crizotinib—TYRO3—lymphoid tissue—ocular cancer	0.00276	0.0114	CbGeAlD
Crizotinib—RIPK2—epithelium—ocular cancer	0.00275	0.0114	CbGeAlD
Crizotinib—TYK2—retina—ocular cancer	0.00275	0.0114	CbGeAlD
Crizotinib—LYN—lymphoid tissue—ocular cancer	0.00275	0.0114	CbGeAlD
Crizotinib—MAP4K1—lymphoid tissue—ocular cancer	0.0027	0.0112	CbGeAlD
Crizotinib—RPS6KB1—eye—ocular cancer	0.00269	0.0111	CbGeAlD
Crizotinib—RPS6KB1—retina—ocular cancer	0.00266	0.011	CbGeAlD
Crizotinib—AXL—eye—ocular cancer	0.00266	0.011	CbGeAlD
Crizotinib—IGF1R—lymphoid tissue—ocular cancer	0.00265	0.011	CbGeAlD
Crizotinib—AXL—retina—ocular cancer	0.00264	0.0109	CbGeAlD
Crizotinib—MAP4K2—lymphoid tissue—ocular cancer	0.00262	0.0108	CbGeAlD
Crizotinib—PTK2—epithelium—ocular cancer	0.00256	0.0106	CbGeAlD
Crizotinib—AURKA—lymphoid tissue—ocular cancer	0.00251	0.0104	CbGeAlD
Crizotinib—RPS6KB1—epithelium—ocular cancer	0.00246	0.0102	CbGeAlD
Crizotinib—MERTK—lymphoid tissue—ocular cancer	0.00243	0.0101	CbGeAlD
Crizotinib—LIMK2—lymphoid tissue—ocular cancer	0.00237	0.00984	CbGeAlD
Crizotinib—FLT3—lymphoid tissue—ocular cancer	0.00235	0.00973	CbGeAlD
Crizotinib—EPHB4—epithelium—ocular cancer	0.00233	0.00964	CbGeAlD
Crizotinib—JAK2—epithelium—ocular cancer	0.00231	0.00958	CbGeAlD
Crizotinib—EPHA2—epithelium—ocular cancer	0.00228	0.00946	CbGeAlD
Crizotinib—YES1—eye—ocular cancer	0.00225	0.00932	CbGeAlD
Crizotinib—YES1—retina—ocular cancer	0.00223	0.00924	CbGeAlD
Crizotinib—TEK—epithelium—ocular cancer	0.00223	0.00923	CbGeAlD
Crizotinib—TAOK3—eye—ocular cancer	0.00222	0.0092	CbGeAlD
Crizotinib—TAOK3—retina—ocular cancer	0.0022	0.00912	CbGeAlD
Crizotinib—SRC—eye—ocular cancer	0.00216	0.00896	CbGeAlD
Crizotinib—SRC—retina—ocular cancer	0.00214	0.00888	CbGeAlD
Crizotinib—PTK2B—lymphoid tissue—ocular cancer	0.00214	0.00886	CbGeAlD
Crizotinib—MAP3K2—lymphoid tissue—ocular cancer	0.00201	0.00833	CbGeAlD
Crizotinib—SRC—epithelium—ocular cancer	0.00198	0.0082	CbGeAlD
Crizotinib—PTK2—lymphoid tissue—ocular cancer	0.00197	0.00816	CbGeAlD
Crizotinib—TBK1—lymphoid tissue—ocular cancer	0.00197	0.00816	CbGeAlD
Crizotinib—TYK2—lymphoid tissue—ocular cancer	0.00196	0.00811	CbGeAlD
Crizotinib—CSF1R—eye—ocular cancer	0.00194	0.00805	CbGeAlD
Crizotinib—RPS6KB1—lymphoid tissue—ocular cancer	0.00189	0.00785	CbGeAlD
Crizotinib—FGR—lymphoid tissue—ocular cancer	0.00188	0.0078	CbGeAlD
Crizotinib—AXL—lymphoid tissue—ocular cancer	0.00187	0.00777	CbGeAlD
Crizotinib—JAK2—lymphoid tissue—ocular cancer	0.00178	0.00738	CbGeAlD
Crizotinib—EPHA2—lymphoid tissue—ocular cancer	0.00176	0.00729	CbGeAlD
Crizotinib—TEK—lymphoid tissue—ocular cancer	0.00171	0.00711	CbGeAlD
Crizotinib—MAP4K5—lymphoid tissue—ocular cancer	0.00171	0.00711	CbGeAlD
Crizotinib—YES1—lymphoid tissue—ocular cancer	0.00158	0.00657	CbGeAlD
Crizotinib—STK10—lymphoid tissue—ocular cancer	0.00157	0.00651	CbGeAlD
Crizotinib—TAOK3—lymphoid tissue—ocular cancer	0.00156	0.00648	CbGeAlD
Crizotinib—ABL1—eye—ocular cancer	0.00153	0.00636	CbGeAlD
Crizotinib—SRC—lymphoid tissue—ocular cancer	0.00152	0.00632	CbGeAlD
Crizotinib—ABL1—retina—ocular cancer	0.00152	0.0063	CbGeAlD
Crizotinib—CSF1R—lymphoid tissue—ocular cancer	0.00137	0.00567	CbGeAlD
Crizotinib—ABL1—lymphoid tissue—ocular cancer	0.00108	0.00448	CbGeAlD
Crizotinib—ABCB1—retina—ocular cancer	0.000473	0.00196	CbGeAlD
Crizotinib—ABCB1—epithelium—ocular cancer	0.000437	0.00181	CbGeAlD
Crizotinib—ABCB1—lymphoid tissue—ocular cancer	0.000336	0.00139	CbGeAlD
Crizotinib—TYK2—Disease—CDKN1A—ocular cancer	1.53e-05	2.01e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN2B—ocular cancer	1.52e-05	2e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—HRAS—ocular cancer	1.51e-05	2e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—HRAS—ocular cancer	1.51e-05	1.99e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CDKN1A—ocular cancer	1.5e-05	1.98e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HDAC1—ocular cancer	1.5e-05	1.97e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—HRAS—ocular cancer	1.5e-05	1.97e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—AKT1—ocular cancer	1.5e-05	1.97e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—AKT1—ocular cancer	1.5e-05	1.97e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—HRAS—ocular cancer	1.49e-05	1.96e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—AKT1—ocular cancer	1.49e-05	1.96e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—HRAS—ocular cancer	1.49e-05	1.96e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—MDM2—ocular cancer	1.49e-05	1.96e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CDKN1B—ocular cancer	1.49e-05	1.96e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—HRAS—ocular cancer	1.48e-05	1.95e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—AKT1—ocular cancer	1.48e-05	1.95e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CDKN1A—ocular cancer	1.48e-05	1.95e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—AKT1—ocular cancer	1.47e-05	1.93e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CCND1—ocular cancer	1.46e-05	1.93e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—HRAS—ocular cancer	1.46e-05	1.93e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—AKT1—ocular cancer	1.46e-05	1.92e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—HRAS—ocular cancer	1.45e-05	1.91e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—EP300—ocular cancer	1.45e-05	1.91e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CDKN1B—ocular cancer	1.45e-05	1.91e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—HRAS—ocular cancer	1.45e-05	1.91e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CDKN1B—ocular cancer	1.44e-05	1.9e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—HRAS—ocular cancer	1.44e-05	1.89e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EP300—ocular cancer	1.43e-05	1.88e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—ocular cancer	1.42e-05	1.88e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CCND1—ocular cancer	1.42e-05	1.87e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CDKN1A—ocular cancer	1.41e-05	1.86e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EP300—ocular cancer	1.41e-05	1.85e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—HRAS—ocular cancer	1.4e-05	1.84e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—AKT1—ocular cancer	1.4e-05	1.84e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MDM2—ocular cancer	1.4e-05	1.84e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—MYC—ocular cancer	1.39e-05	1.84e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—E2F1—ocular cancer	1.39e-05	1.83e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TGFB1—ocular cancer	1.39e-05	1.83e-05	CbGpPWpGaD
Crizotinib—CDK7—Gene Expression—AKT1—ocular cancer	1.39e-05	1.83e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MDM2—ocular cancer	1.38e-05	1.81e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ocular cancer	1.37e-05	1.81e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—AKT1—ocular cancer	1.37e-05	1.81e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—MDM2—ocular cancer	1.37e-05	1.81e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CDKN1A—ocular cancer	1.37e-05	1.81e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—HRAS—ocular cancer	1.36e-05	1.79e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CDKN1B—ocular cancer	1.36e-05	1.79e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EP300—ocular cancer	1.35e-05	1.77e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN2B—ocular cancer	1.34e-05	1.77e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CDKN1A—ocular cancer	1.34e-05	1.76e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—AKT1—ocular cancer	1.34e-05	1.76e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—AKT1—ocular cancer	1.33e-05	1.76e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CDKN1A—ocular cancer	1.33e-05	1.75e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—AKT1—ocular cancer	1.32e-05	1.74e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—AKT1—ocular cancer	1.31e-05	1.73e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—AKT1—ocular cancer	1.31e-05	1.73e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—AKT1—ocular cancer	1.31e-05	1.72e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MDM2—ocular cancer	1.31e-05	1.72e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EP300—ocular cancer	1.3e-05	1.72e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—MDM2—ocular cancer	1.3e-05	1.71e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—AKT1—ocular cancer	1.29e-05	1.7e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—AKT1—ocular cancer	1.28e-05	1.69e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—AKT1—ocular cancer	1.28e-05	1.68e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CDKN1B—ocular cancer	1.27e-05	1.68e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—EP300—ocular cancer	1.27e-05	1.68e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—AKT1—ocular cancer	1.27e-05	1.67e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MDM2—ocular cancer	1.27e-05	1.67e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EP300—ocular cancer	1.27e-05	1.67e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GNA11—ocular cancer	1.26e-05	1.67e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—MYC—ocular cancer	1.26e-05	1.67e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—TGFB1—ocular cancer	1.26e-05	1.66e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—ocular cancer	1.26e-05	1.66e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CDKN1B—ocular cancer	1.26e-05	1.66e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—CDKN1B—ocular cancer	1.25e-05	1.65e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CDKN1A—ocular cancer	1.25e-05	1.65e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MYC—ocular cancer	1.24e-05	1.64e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TGFB1—ocular cancer	1.24e-05	1.63e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—AKT1—ocular cancer	1.24e-05	1.63e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—E2F1—ocular cancer	1.23e-05	1.62e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—HRAS—ocular cancer	1.23e-05	1.62e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—HRAS—ocular cancer	1.23e-05	1.62e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MYC—ocular cancer	1.22e-05	1.61e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TGFB1—ocular cancer	1.22e-05	1.61e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CCND1—ocular cancer	1.22e-05	1.6e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—HRAS—ocular cancer	1.21e-05	1.59e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—AKT1—ocular cancer	1.2e-05	1.58e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—MDM2—ocular cancer	1.2e-05	1.58e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CCND1—ocular cancer	1.2e-05	1.58e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CDKN1B—ocular cancer	1.19e-05	1.57e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EP300—ocular cancer	1.19e-05	1.57e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CDKN1B—ocular cancer	1.19e-05	1.57e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HRAS—ocular cancer	1.18e-05	1.56e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—HRAS—ocular cancer	1.18e-05	1.55e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HRAS—ocular cancer	1.18e-05	1.55e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CDKN1A—ocular cancer	1.18e-05	1.55e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GNAQ—ocular cancer	1.18e-05	1.55e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MYC—ocular cancer	1.17e-05	1.54e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TGFB1—ocular cancer	1.17e-05	1.54e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—HRAS—ocular cancer	1.17e-05	1.54e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CDKN1A—ocular cancer	1.16e-05	1.53e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CDKN1B—ocular cancer	1.16e-05	1.53e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—CDKN1A—ocular cancer	1.16e-05	1.52e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—MDM2—ocular cancer	1.15e-05	1.52e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—ocular cancer	1.15e-05	1.51e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CCND1—ocular cancer	1.14e-05	1.5e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MYC—ocular cancer	1.14e-05	1.5e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TGFB1—ocular cancer	1.13e-05	1.49e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EP300—ocular cancer	1.12e-05	1.47e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HRAS—ocular cancer	1.11e-05	1.46e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CCND1—ocular cancer	1.1e-05	1.46e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EP300—ocular cancer	1.1e-05	1.45e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CDKN1A—ocular cancer	1.1e-05	1.45e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—EP300—ocular cancer	1.1e-05	1.45e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CDKN1B—ocular cancer	1.1e-05	1.45e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CDKN1A—ocular cancer	1.1e-05	1.45e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—HRAS—ocular cancer	1.1e-05	1.44e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—HRAS—ocular cancer	1.09e-05	1.43e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—AKT1—ocular cancer	1.09e-05	1.43e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—AKT1—ocular cancer	1.08e-05	1.43e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HRAS—ocular cancer	1.08e-05	1.42e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CDKN1A—ocular cancer	1.07e-05	1.41e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—AKT1—ocular cancer	1.06e-05	1.4e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—MDM2—ocular cancer	1.06e-05	1.4e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CDKN1B—ocular cancer	1.05e-05	1.39e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EP300—ocular cancer	1.05e-05	1.38e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—AKT1—ocular cancer	1.05e-05	1.38e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—EP300—ocular cancer	1.04e-05	1.38e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HRAS—ocular cancer	1.04e-05	1.37e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—AKT1—ocular cancer	1.04e-05	1.37e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—AKT1—ocular cancer	1.04e-05	1.37e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—AKT1—ocular cancer	1.03e-05	1.36e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MDM2—ocular cancer	1.03e-05	1.35e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—ocular cancer	1.02e-05	1.35e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EP300—ocular cancer	1.02e-05	1.34e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CDKN1A—ocular cancer	1.01e-05	1.33e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—ocular cancer	1.01e-05	1.33e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—HRAS—ocular cancer	9.93e-06	1.31e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—AKT1—ocular cancer	9.78e-06	1.29e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—HRAS—ocular cancer	9.76e-06	1.29e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MYC—ocular cancer	9.75e-06	1.29e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TGFB1—ocular cancer	9.73e-06	1.28e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CDKN1B—ocular cancer	9.71e-06	1.28e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CDKN1A—ocular cancer	9.71e-06	1.28e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—AKT1—ocular cancer	9.67e-06	1.27e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—EP300—ocular cancer	9.63e-06	1.27e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—ocular cancer	9.63e-06	1.27e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—HRAS—ocular cancer	9.62e-06	1.27e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MYC—ocular cancer	9.62e-06	1.27e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MDM2—ocular cancer	9.61e-06	1.27e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TGFB1—ocular cancer	9.59e-06	1.26e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—MYC—ocular cancer	9.58e-06	1.26e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—AKT1—ocular cancer	9.58e-06	1.26e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—TGFB1—ocular cancer	9.56e-06	1.26e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—AKT1—ocular cancer	9.5e-06	1.25e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN1B—ocular cancer	9.37e-06	1.24e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—ocular cancer	9.34e-06	1.23e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—EP300—ocular cancer	9.24e-06	1.22e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HRAS—ocular cancer	9.21e-06	1.21e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—AKT1—ocular cancer	9.2e-06	1.21e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MYC—ocular cancer	9.12e-06	1.2e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TGFB1—ocular cancer	9.1e-06	1.2e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CDKN1A—ocular cancer	8.96e-06	1.18e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCND1—ocular cancer	8.94e-06	1.18e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HRAS—ocular cancer	8.93e-06	1.18e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HRAS—ocular cancer	8.92e-06	1.18e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—ocular cancer	8.86e-06	1.17e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TGFB1—ocular cancer	8.83e-06	1.16e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1B—ocular cancer	8.77e-06	1.16e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—AKT1—ocular cancer	8.77e-06	1.16e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—HRAS—ocular cancer	8.71e-06	1.15e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AKT1—ocular cancer	8.68e-06	1.14e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HRAS—ocular cancer	8.67e-06	1.14e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN1A—ocular cancer	8.65e-06	1.14e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AKT1—ocular cancer	8.62e-06	1.14e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—EP300—ocular cancer	8.53e-06	1.12e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AKT1—ocular cancer	8.49e-06	1.12e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MDM2—ocular cancer	8.41e-06	1.11e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—ocular cancer	8.39e-06	1.11e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—TGFB1—ocular cancer	8.37e-06	1.1e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCND1—ocular cancer	8.37e-06	1.1e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EP300—ocular cancer	8.23e-06	1.08e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HRAS—ocular cancer	8.15e-06	1.07e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AKT1—ocular cancer	8.13e-06	1.07e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1A—ocular cancer	8.09e-06	1.07e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—ocular cancer	8.01e-06	1.06e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—ocular cancer	7.9e-06	1.04e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AKT1—ocular cancer	7.88e-06	1.04e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AKT1—ocular cancer	7.88e-06	1.04e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GNA11—ocular cancer	7.79e-06	1.03e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EP300—ocular cancer	7.7e-06	1.02e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—AKT1—ocular cancer	7.69e-06	1.01e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1B—ocular cancer	7.68e-06	1.01e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HRAS—ocular cancer	7.66e-06	1.01e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AKT1—ocular cancer	7.66e-06	1.01e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HRAS—ocular cancer	7.55e-06	9.96e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—HRAS—ocular cancer	7.53e-06	9.92e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—ocular cancer	7.49e-06	9.87e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MDM2—ocular cancer	7.45e-06	9.82e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—ocular cancer	7.43e-06	9.79e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—TGFB1—ocular cancer	7.41e-06	9.77e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCND1—ocular cancer	7.33e-06	9.66e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—ocular cancer	7.27e-06	9.58e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GNAQ—ocular cancer	7.24e-06	9.55e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AKT1—ocular cancer	7.2e-06	9.49e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—ocular cancer	7.17e-06	9.45e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HRAS—ocular cancer	7.16e-06	9.44e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TGFB1—ocular cancer	7.15e-06	9.43e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—HRAS—ocular cancer	7.14e-06	9.41e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1A—ocular cancer	7.09e-06	9.34e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HRAS—ocular cancer	6.96e-06	9.17e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1B—ocular cancer	6.8e-06	8.96e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKT1—ocular cancer	6.76e-06	8.91e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EP300—ocular cancer	6.75e-06	8.89e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—ocular cancer	6.71e-06	8.84e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TGFB1—ocular cancer	6.7e-06	8.82e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKT1—ocular cancer	6.67e-06	8.79e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKT1—ocular cancer	6.65e-06	8.76e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—HRAS—ocular cancer	6.59e-06	8.69e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCND1—ocular cancer	6.49e-06	8.55e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKT1—ocular cancer	6.33e-06	8.34e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—HRAS—ocular cancer	6.32e-06	8.33e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—AKT1—ocular cancer	6.31e-06	8.31e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1A—ocular cancer	6.28e-06	8.27e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKT1—ocular cancer	6.14e-06	8.09e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EP300—ocular cancer	5.97e-06	7.87e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—ocular cancer	5.89e-06	7.76e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—ocular cancer	5.88e-06	7.75e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TGFB1—ocular cancer	5.86e-06	7.73e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—HRAS—ocular cancer	5.84e-06	7.69e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—AKT1—ocular cancer	5.82e-06	7.67e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HRAS—ocular cancer	5.63e-06	7.42e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—EP300—ocular cancer	5.6e-06	7.38e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—AKT1—ocular cancer	5.58e-06	7.36e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—ocular cancer	5.51e-06	7.26e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HRAS—ocular cancer	5.27e-06	6.95e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—ocular cancer	5.2e-06	6.86e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TGFB1—ocular cancer	5.19e-06	6.84e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—AKT1—ocular cancer	5.15e-06	6.79e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKT1—ocular cancer	4.97e-06	6.55e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—ocular cancer	4.83e-06	6.36e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT1—ocular cancer	4.65e-06	6.13e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HRAS—ocular cancer	4.62e-06	6.08e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—ocular cancer	4.27e-06	5.63e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—EP300—ocular cancer	4.23e-06	5.57e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HRAS—ocular cancer	4.09e-06	5.39e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT1—ocular cancer	4.08e-06	5.37e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT1—ocular cancer	3.61e-06	4.76e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AKT1—ocular cancer	3.38e-06	4.46e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—EP300—ocular cancer	2.6e-06	3.43e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKT1—ocular cancer	2.55e-06	3.37e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKT1—ocular cancer	1.57e-06	2.07e-06	CbGpPWpGaD
